Activated Recombinant Protein C in Septic Shock Early After Liver Transplantation: A Case Report

Transplantation Proceedings

Volumn 40, Issue 6, 2008, Pages 2070-2072

  Feltracco, P ^a   Bortolato, A ^a   Rizzi, S ^a   Barbieri, S ^a   Furnari, M ^a   Serra, E ^a   Milevoj, M ^a   Ori, C ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN;

ABDOMINAL DISTENSION; ABSENCE OF SIDE EFFECTS; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANAMNESIS; ARTICLE; CASE REPORT; CHOLEDOCHOJEJUNOSTOMY; CLINICAL FEATURE; CONTINUOUS INFUSION; CONVALESCENCE; DISEASE COURSE; ENDOTRACHEAL INTUBATION; GENERAL CONDITION DETERIORATION; GENERAL CONDITION IMPROVEMENT; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; INTERMITTENT POSITIVE PRESSURE VENTILATION; LIVER TRANSPLANTATION; MALE; POSTOPERATIVE PAIN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SEPTIC SHOCK; TREATMENT OUTCOME;

CROSS INFECTION; FIBRINOLYTIC AGENTS; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PNEUMONIA; POSTOPERATIVE COMPLICATIONS; PROTEIN C; RECOMBINANT PROTEINS; SHOCK, SEPTIC;

EID: 48049085033     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.05.030     Document Type: Article

References (12)

1. Marik P.E., and Lipman J. The definition of septic shock: implications for treatment. Crit Care Resusc 9 (2007) 101
2. Dellinger R.P., Carlet J.M., Masur H., et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32 (2004) 858
3. Kulkarni S., Naureckas E., and Cronin D.C. Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis. Transplantation 75 (2003) 899
4. Bernard G.R., Vincent J.-L., Laterre P.-F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Eng J Med 344 (2001) 699
5. Parrillo J.E. Severe sepsis and therapy with activated Protein C. N Engl J Med 353 (2005) 1398
6. Browne E., Cressey D.M., Agarwal K., et al. The use of drotrecogin alfa (activated) in a patient with recent orthotopic liver transplant. Anaesthesia 62 (2007) 282
7. Grinnel B.W., Herman R.B., and Yan S.B. Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide. Glycobiology 4 (1994) 221
8. Hoffman J.N., Vollmar B., Laschke M.W., et al. Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia. Crit Care Med 32 (2004) 1011
9. Ernst F.R., Johnston J.A., Pulgar S., et al. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs. Curr Med Res Opin 23 (2007) 235
10. Vincent J.L., Bernard G.R., Beale R., et al. DRotregogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33 (2005) 2266
11. De Backer D. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis. Drug Saf 30 (2007) 995
12. Barie P.S., Williams M.D., McCollam J.S., et al. Benefit/risk profile od drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg 188 (2004) 212